Alpha-1-proteinase inhibitor
Also known as: A1PI, AAT, Alpha-1-antitrypsin, Alpha‑1 antitrypsin, Glassia, Prolastin, Prolastin-C, SERPINA1, Zemaira
Source Alpha-1-proteinase inhibitor at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Alpha-1-proteinase inhibitor (A1PI), also called alpha‑1 antitrypsin, is a serpin‑type protein used as a prescription drug delivered by intravenous infusion. It is approved for augmentation therapy in patients with hereditary alpha‑1 antitrypsin deficiency who develop lung disease, aiming to restore the balance between neutrophil elastase and its inhibitor and to slow emphysema progression.
Mechanism of Action
A1PI circulates from the liver to the lung where it covalently binds and inactivates neutrophil elastase, a serine protease that degrades elastin and other extracellular matrix proteins. By neutralising excess elastase, it preserves elastin fibers, limits tissue destruction, and exerts broader anti‑protease and immunomodulatory effects that can dampen inflammation in the pulmonary micro‑environment.
What the Research Shows
Clinical literature documents that regular intravenous augmentation restores antiprotease activity in the lungs of individuals with AAT deficiency, showing cumulative evidence of slowed decline in lung function and reduced emphysema progression. Reviews highlight the need for further trials to define optimal dosing and patient selection. Observational and laboratory data suggest a possible role for A1PI in preventing bronchopulmonary dysplasia in preterm infants, but no trial has yet demonstrated clear benefit. Ongoing research also explores recombinant forms to address supply constraints and evaluates A1PI as a urinary biomarker for infection, reflecting its broad biological relevance.
Reported Benefits
In patients with alpha‑1 antitrypsin deficiency and pulmonary involvement, augmentation therapy has been associated with a measurable slowing of forced expiratory decline and reduced radiographic progression of emphysema. The therapy also restores local antiprotease activity and may provide systemic immunomodulation. Preliminary data suggest potential protective effects in neonatal lung injury, though this remains investigational.
Limitations of the Evidence
Evidence for benefit outside AAT deficiency, such as in bronchopulmonary dysplasia, is limited to early‑phase studies and meta‑analyses without definitive trial outcomes. Recombinant A1PI products are still experimental and not approved, leaving plasma‑derived material as the sole source, which may not meet demand. The optimal dosing schedule and patient subgroups requiring treatment are still being refined.
Safety Considerations
Plasma‑derived A1PI is generally well tolerated, but infusion‑related reactions and rare allergic responses can occur. Manufacturing includes viral clearance steps, yet a residual theoretical risk of pathogen contamination exists. Safety data for recombinant forms are limited, and long‑term adverse‑event profiles beyond the approved indication have not been fully established.
How It Is Administered
Alpha‑1‑proteinase inhibitor is administered intravenously, typically as scheduled infusions (e.g., weekly or bi‑weekly) using commercially available plasma‑derived formulations. Different products vary in purification methods and concentration, but all are delivered by infusion over a period of time under clinical supervision.
Routes of Administration
Goals & Uses
- Reduction of acute exacerbationsPulmonaryLow
- Slowing emphysema progression in alpha-1-antitrypsin deficiencyPulmonary / Disease ModificationModerate
- Raising serum A1PI above protective thresholdBiochemical/Surrogate EndpointHigh
- Augmentation therapy for A1AT deficiencyPulmonary DiseaseHigh
- Prevention of liver disease progressionHepatic DiseaseModerate
Contraindications
- IgA deficiency with anti-IgA antibodiesImmunologicalHigh
- Hypersensitivity to alpha‑1 antitrypsin productAllergyHigh
- Hypersensitivity to A1PI or any product excipientImmunologicalHigh
- Severe liver dysfunctionHepaticModerate
- Alpha-1-antitrypsin deficiency without emphysema (Pi*MZ heterozygotes with normal levels)Indication MismatchModerate
Adverse Effects
- AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
- HeadacheNeurologicCommonPain in the head or upper neck
- Upper respiratory tract infectionInfectiousCommon
- Theoretical risk of transmissible pathogensInfectiousRare
- Infusion-related reactionsHypersensitivityCommon
- Infusion-related reactions (fever, chills, flushing)Immunological / InfusionUncommon
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Anticoagulants (e.g., warfarin)Moderate
- Tobacco smoke / cigarette smokingHigh
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Patients with cardiac or renal impairmentComorbidityRelative
- Pediatric patients (<12 years)PediatricRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Alpha‑1 antitrypsin deficiencyEMA-approved plasma‑derived and recombinant forms.
- United StatesApprovedApproved: Alpha‑1 antitrypsin deficiency (augmentation therapy)FDA-approved products include Prolastin, Zemaira, Glassia.
- United KingdomApprovedApproved: Alpha‑1 antitrypsin deficiencyMHRA-approved for augmentation therapy.
FDA‑approved (e.g., Prolastin, Zemaira, Glassia) for augmentation therapy in A1AT deficiency; also approved in EU and UK.
Evidence & Sources
- Journal ArticleModerateVan Marter LJ2005-01-01T00:00:00.000000Z
- Journal ArticleModerateRitscher D, Russi EW1999-01-01T00:00:00.000000Z
- Journal ArticleModerateMasajtis-Zagajewska A, Nowicki M2017-01-01T00:00:00.000000Z
- Journal ArticleModerateCampos M, Lascano J2017-01-01T00:00:00.000000Z
- Journal ArticleModerateWerb Z, et al.1982-01-01T00:00:00.000000Z
- Journal ArticleModerateKarnaukhova E, Ophir Y, Golding B2006-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is Alpha‑1‑proteinase inhibitor officially approved to treat?
It is approved for augmentation therapy in individuals with hereditary alpha‑1 antitrypsin deficiency who have developed lung disease, such as emphysema, to restore antiprotease balance.
Can Alpha‑1‑proteinase inhibitor prevent bronchopulmonary dysplasia in premature infants?
Current evidence is limited to observational and early‑phase studies; no randomized trial has shown a definitive preventive benefit, so its use for this purpose remains investigational.
Are there any safety concerns with the intravenous product?
The main concerns are infusion‑related reactions and a theoretical risk of pathogen contamination despite viral inactivation steps; allergic responses are rare but possible.
Why are recombinant versions being developed?
Plasma‑derived A1PI supply may not meet clinical demand and carries a residual contamination risk; recombinant forms aim to provide a scalable, potentially safer alternative, though they are not yet approved.
How is the drug given to patients?
It is given by intravenous infusion, usually on a regular schedule such as weekly or every two weeks, using sterile formulations prepared from pooled human plasma.
What is Alpha-1-proteinase inhibitor?
Alpha-1-proteinase inhibitor (A1PI), also called alpha‑1 antitrypsin, is a serpin‑type protein used as a prescription drug delivered by intravenous infusion. It is approved for augmentation therapy in patients with hereditary alpha‑1 antitrypsin deficiency who develop lung disease, aiming to restore the balance between neutrophil elastase and its inhibitor and to slow emphysema progression.
What is Alpha-1-proteinase inhibitor used for?
Alpha-1-proteinase inhibitor is educationally associated with: Reduction of acute exacerbations, Slowing emphysema progression in alpha-1-antitrypsin deficiency, Raising serum A1PI above protective threshold, Augmentation therapy for A1AT deficiency, Prevention of liver disease progression. Educational only — not medical advice.
How is Alpha-1-proteinase inhibitor administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Alpha-1-proteinase inhibitor?
Reported adverse effects include: Anaphylaxis, Headache, Upper respiratory tract infection, Theoretical risk of transmissible pathogens, Infusion-related reactions, Infusion-related reactions (fever, chills, flushing), Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Alpha-1-proteinase inhibitor?
Recorded contraindications: IgA deficiency with anti-IgA antibodies, Hypersensitivity to alpha‑1 antitrypsin product, Hypersensitivity to A1PI or any product excipient, Severe liver dysfunction, Alpha-1-antitrypsin deficiency without emphysema (Pi*MZ heterozygotes with normal levels). Consult a qualified clinician before use.